177 related articles for article (PubMed ID: 19998405)
1. Human tissue transglutaminase is inhibited by pharmacologic and chemical acetylation.
Lai TS; Davies C; Greenberg CS
Protein Sci; 2010 Feb; 19(2):229-35. PubMed ID: 19998405
[TBL] [Abstract][Full Text] [Related]
2. Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries.
Lai TS; Liu Y; Tucker T; Daniel KR; Sane DC; Toone E; Burke JR; Strittmatter WJ; Greenberg CS
Chem Biol; 2008 Sep; 15(9):969-78. PubMed ID: 18804034
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of transglutaminase 2 reduces efferocytosis in human macrophages: Role of CD14 and SR-AI receptors.
Eligini S; Fiorelli S; Tremoli E; Colli S
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):922-30. PubMed ID: 27378395
[TBL] [Abstract][Full Text] [Related]
4. TGM2 and implications for human disease: role of alternative splicing.
Lai TS; Greenberg CS
Front Biosci (Landmark Ed); 2013 Jan; 18(2):504-19. PubMed ID: 23276939
[TBL] [Abstract][Full Text] [Related]
5. Partial acetylation of lysine residues improves intraprotein cross-linking.
Guo X; Bandyopadhyay P; Schilling B; Young MM; Fujii N; Aynechi T; Guy RK; Kuntz ID; Gibson BW
Anal Chem; 2008 Feb; 80(4):951-60. PubMed ID: 18201069
[TBL] [Abstract][Full Text] [Related]
6. Effect of tissue transglutaminase on the solubility of proteins containing expanded polyglutamine repeats.
Lai TS; Tucker T; Burke JR; Strittmatter WJ; Greenberg CS
J Neurochem; 2004 Mar; 88(5):1253-60. PubMed ID: 15009681
[TBL] [Abstract][Full Text] [Related]
7. Genomic variants reveal differential evolutionary constraints on human transglutaminases and point towards unrecognized significance of transglutaminase 2.
Thangaraju K; Király R; Demény MA; András Mótyán J; Fuxreiter M; Fésüs L
PLoS One; 2017; 12(3):e0172189. PubMed ID: 28248968
[TBL] [Abstract][Full Text] [Related]
8. Transglutaminase-catalyzed crosslinking in neurological disease: from experimental evidence to therapeutic inhibition.
Hoffner G; André W; Vanhoutteghem A; Souès S; Djian P
CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):217-31. PubMed ID: 19811443
[TBL] [Abstract][Full Text] [Related]
9. Novel peptide GX1 inhibits angiogenesis by specifically binding to transglutaminase-2 in the tumorous endothelial cells of gastric cancer.
Lei Z; Chai N; Tian M; Zhang Y; Wang G; Liu J; Tian Z; Yi X; Chen D; Li X; Yu P; Hu H; Xu B; Jian C; Bian Z; Guo H; Wang J; Peng S; Nie Y; Huang N; Hu S; Wu K
Cell Death Dis; 2018 May; 9(6):579. PubMed ID: 29785022
[TBL] [Abstract][Full Text] [Related]
10. Lysine-rich histone (H1) is a lysyl substrate of tissue transglutaminase: possible involvement of transglutaminase in the formation of nuclear aggregates in (CAG)(n)/Q(n) expansion diseases.
Cooper AJ; Wang J; Pasternack R; Fuchsbauer HL; Sheu RK; Blass JP
Dev Neurosci; 2000; 22(5-6):404-17. PubMed ID: 11111157
[TBL] [Abstract][Full Text] [Related]
11. Transglutaminases as possible therapeutic targets in neurodegenerative diseases.
Martin A; De Vivo G; Ricotta M; Iannuzzi M; Gentile V
Recent Pat CNS Drug Discov; 2010 Nov; 5(3):195-202. PubMed ID: 20636272
[TBL] [Abstract][Full Text] [Related]
12. Transglutaminase 6 interacts with polyQ proteins and promotes the formation of polyQ aggregates.
Guan WJ; Xia KD; Ma YT; Liu YT; Shi YT; Jiang H; Shen L; Xia K; Li JD; Tang BS; Wang JL
Biochem Biophys Res Commun; 2013 Jul; 437(1):94-100. PubMed ID: 23800413
[TBL] [Abstract][Full Text] [Related]
13. Transglutaminase inhibition as a possible therapeutical approach to protect cells from death in neurodegenerative diseases.
Iannaccone M; Serretiello E; De Vivo G; Martin A; Stefanile A; Titta F; Gentile V
Recent Pat CNS Drug Discov; 2013 Aug; 8(2):161-8. PubMed ID: 23688272
[TBL] [Abstract][Full Text] [Related]
14. Kinetic analysis of the interaction of tissue transglutaminase with a nonpeptidic slow-binding inhibitor.
Case A; Stein RL
Biochemistry; 2007 Jan; 46(4):1106-15. PubMed ID: 17240993
[TBL] [Abstract][Full Text] [Related]
15. Structure-Activity Relationships of Potent, Targeted Covalent Inhibitors That Abolish Both the Transamidation and GTP Binding Activities of Human Tissue Transglutaminase.
Akbar A; McNeil NMR; Albert MR; Ta V; Adhikary G; Bourgeois K; Eckert RL; Keillor JW
J Med Chem; 2017 Sep; 60(18):7910-7927. PubMed ID: 28858494
[TBL] [Abstract][Full Text] [Related]
16. Tissue transglutaminase expression and activity in normal and glaucomatous human trabecular meshwork cells and tissues.
Tovar-Vidales T; Roque R; Clark AF; Wordinger RJ
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):622-8. PubMed ID: 18235007
[TBL] [Abstract][Full Text] [Related]
17. Transglutaminase 2 accelerates vascular calcification in chronic kidney disease.
Chen NX; O'Neill K; Chen X; Kiattisunthorn K; Gattone VH; Moe SM
Am J Nephrol; 2013; 37(3):191-8. PubMed ID: 23466870
[TBL] [Abstract][Full Text] [Related]
18. Transglutaminase 2 undergoes a large conformational change upon activation.
Pinkas DM; Strop P; Brunger AT; Khosla C
PLoS Biol; 2007 Dec; 5(12):e327. PubMed ID: 18092889
[TBL] [Abstract][Full Text] [Related]
19. Computational analyses of the effect of novel amino acid clusters of human transglutaminase 2 on its structure and function.
Thangaraju K; Király R; Mótyán JA; Ambrus VA; Fuxreiter M; Fésüs L
Amino Acids; 2017 Mar; 49(3):605-614. PubMed ID: 27627884
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of tissue transglutaminase.
Keillor JW; Apperley KY; Akbar A
Trends Pharmacol Sci; 2015 Jan; 36(1):32-40. PubMed ID: 25500711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
